>>13534532>alneva is working on an a dead virus vaccine which should be out eventually.Over 4,000 volunteers have been recruited in the United Kingdom (Press release) for the Phase 3 immunogenicity trial “Cov-Compare”, which compares VLA2001 against AstraZeneca’s conditionally approved vaccine, Vaxzevria (Press release). Topline data are expected early in fourth quarter 2021.
Valneva reported positive Phase 1/2 trial data for VLA2001 at the beginning of April 2021 (Press release). VLA2001 was well tolerated with no safety concerns identified. In the high dose group, IgG seroconversion rate was 100%, and neutralizing antibody titers were at or above levels generally seen in convalescent sera. Based on the data assessed, the Company has decided to advance the high dose into the Phase 3 clinical trial.
